Simultaneous determination of azilsartan and chlorthalidone in rat and human plasma by liquid chromatography-electrospray tandem mass spectrometry

Ramakrishna, Rachumallu; Puttrevu, Santosh Kumar; Bhateria, Manisha; Bala, Veenu; Sharma, Vishnu L.; Bhatta, Rabi Sankar

doi:10.1016/j.jchromb.2015.03.018

Cited by 26 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More importantly, we provide the first evidence that oral administration of azilsartan, a newly developed AT1R blocker approved by the U.S. Food and Drug Administration (FDA) for hypertension treatment [11], rescues the apoptosis of dopaminergic neurons and relieves the characteristic parkinsonian symptoms in a PD model induced by rotenone. These results support the application of AT1R blockers in the therapy of PD, and strengthen the notion that many therapeutic agents may possess pleiotropic action in addition to their main applications.…”

Section: Introductionmentioning

confidence: 99%

Azilsartan ameliorates apoptosis of dopaminergic neurons and rescues characteristic parkinsonian behaviors in a rat model of Parkinson’s disease

Gao

Jiang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Loss of dopaminergic neurons within the substantia nigra (SN) is a pathological hallmark of Parkinsons disease (PD), which leads to the onset of motor symptoms. Previously, our in vitro studies revealed that Angiotensin II (Ang II) induced apoptosis of dopaminergic neurons through its type 1 receptor (AT1R), but these findings needed to be confirmed via animal experiments. Here, using a rotenone-induced rat model of PD, we observed an overactivation of Ang II/AT1R axis in the SN, since Ang II level and AT1R expression were markedly increased. Furthermore, we provided in vivo evidence that Ang II directly elicited apoptosis of dopaminergic neurons via activation of AT1R in the SN of rats. More importantly, we showed for the first time that oral administration of azilsartan, a newly developed AT1R blocker approved by the U.S. Food and Drug Administration for hypertension treatment, rescued the apoptosis of dopaminergic neurons and relieved the characteristic parkinsonian symptoms in PD rats. These results support the application of AT1R blockers in PD therapy, and strengthen the notion that many therapeutic agents may possess pleiotropic action in addition to their main applications.

show abstract

Section: Introductionmentioning

confidence: 99%

Azilsartan ameliorates apoptosis of dopaminergic neurons and rescues characteristic parkinsonian behaviors in a rat model of Parkinson’s disease

Gao

Jiang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Higher temperature may increase the solubility of donepezil in aqueous solution and strengthen the desorption process , resulting in an obvious decrease of sorption amount of donepezil. However, the sorption amount of the MIP adsorbents for donepezil changed little with increasing temperature due to the conformational memory formed by the imprinting and crosslinking reactions , suggesting the good imprinting effect and selectivity for donepezil using the MIP adsorbents.…”

Section: Resultsmentioning

confidence: 99%

Determination of donepezil in serum samples using molecularly imprinted polymer nanoparticles followed by high‐performance liquid chromatography with ultraviolet detection

Khansari

Bikloo

Shahreza

2016

J of Separation Science

View full text Add to dashboard Cite

A molecularly imprinted polymer designed for the selective extraction of donepezil from serum samples was synthesized using a noncovalent molecular imprinting approach. The molecularly imprinted polymer was evaluated chromatographically and then its affinity for donepezil was confirmed by solid-phase extraction. The optimal conditions for solid-phase extraction were provided by cartridge conditioning using acidified water purified from a Milli-Q system, sample loading under basic aqueous conditions, clean-up using acetonitrile, and elution with methanol/tetrahydrofuran. Desirable molecular recognition properties of the molecularly imprinted polymer led to good donepezil recoveries (90-102%). The data indicated that the imprinted polymer has a perfect selectivity and affinity for donepezil and could be used for selective extraction and analysis of donepezil in human serum.

show abstract

“…Chromatographic separation of the analytes was screened on three analytical columns having a C 18 stationary phase. In the literature the C 18 stationary phase is favorable for both molecules (Bharathi, Hotha, Chatki, Satyanarayana, & Venkateswarlu, ; Ramakrishna et al, ), namely Hypersil Gold C 18 (50 × 2.1 mm, 1.9 μm), Zorbax Eclipse Plus C 18 (50 × 2.1 mm, 1.8 μm) and UPLC BEH C 18 (50 × 2.1 mm, 1.7 μm), under isocratic conditions to obtain adequate response, acceptable peak shape and a shorter analysis time. Elution of analytes was tried with different mobile phases, consisting of methanol–acetonitrile in combination with ammonium acetate–acetic acid and ammonium formate–formic acid buffers.…”

Section: Resultsmentioning

confidence: 99%

“…On the other hand, CHL has been determined in biological matrices by HPLC‐UV (Guelen et al, ; Muirhead & Christie, ; Rosenberg et al, ; Salado & Vera‐Avila, ) and GC‐flame ionization detector (FID) detection (Fleuren & Van Rossum, ). There are several reports for the combination of CAN with drugs other than CHL (Bharathi, Hotha, Chatki, Satyanarayana, & Venkateswarlu, ; Erk, ; Levi, Wuerzner, Ezan, & Pruvost, ) and combination of CHL with drugs other than CAN (Elgawish, Mostafa, & Elshanawaneb, ; Ramakrishna et al, ). However, to date there are no bioanalytical methods for the simultaneous assessment of CAN and CHL in human plasma.…”

Section: Introductionmentioning

confidence: 99%

The simultaneous UPLC–MS/MS determination of emerging drug combination; candesartan and chlorthalidone in human plasma and its application

Patel

Jangid

Suhagia

et al. 2017

Biomedical Chromatography

View full text Add to dashboard Cite

A novel, precise, sensitive and accurate ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method has been developed for the simultaneous determination of a novel drug combination, candesartan (CAN) and chlorthalidone (CHL), in human plasma. Chromatographic separation was achieved on Waters Acquity UPLC BEH C (50 × 2.1 mm, 1.7 μm). Mobile phase consisting of 1 mm ammonium acetate in water-acetonitrile (20:80 v/v) was used. The total chromatographic runtime was 1.9 min with retention times for CAN and CHL at 0.7 and 1.1 min respectively. Ionization and detection of analytes and internal standards was performed on a triple quadrupole mass spectrometer, operating in the multiple reaction monitoring and negative ionization mode. Quantitation was done to monitor protonated precursor → product ion transition of m/z 439.2 → 309.0 for CAN, 337.0 → 189.8 for CHL and 443.2 → 312.1 for candesartan D4 and 341.0 → 189.8 for chlorthalidone D4. The method was validated over a wide dynamic concentration range of 2.0-540.0 ng/mL for candesartan and 1.0-180.0 ng/mL for chlorthalidone. The validated method was successfully applied for the assay of CAN and CHL in healthy volunteers.

show abstract

Simultaneous determination of azilsartan and chlorthalidone in rat and human plasma by liquid chromatography-electrospray tandem mass spectrometry

Cited by 26 publications

References 18 publications

Azilsartan ameliorates apoptosis of dopaminergic neurons and rescues characteristic parkinsonian behaviors in a rat model of Parkinson’s disease

Azilsartan ameliorates apoptosis of dopaminergic neurons and rescues characteristic parkinsonian behaviors in a rat model of Parkinson’s disease

Determination of donepezil in serum samples using molecularly imprinted polymer nanoparticles followed by high‐performance liquid chromatography with ultraviolet detection

The simultaneous UPLC–MS/MS determination of emerging drug combination; candesartan and chlorthalidone in human plasma and its application

Contact Info

Product

Resources

About